Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

Taysha Gene Therapies, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

TSHA-102 GRANTED BREAKTHROUGH THERAPY DESIGNATION BY FDA FINALIZED FDA ALIGNMENT ON REVEAL PIVOTAL TRIAL PROTOCOL AND SAP, INCLUDING 6-MONTH INTERIM ANALYSIS THAT MAY EXPEDITE BLA SUBMISSION, WHICH WAS ENABLED BY THE RIGOROUS DEVELOPMENTAL MILESTONE EVALUATION IN PART A REVEAL PHASE 1/2 TRIALS SHOWING AN UNPRECEDENTED RESPONSE RATE DOSING OF FIRST PATIENT IN REVEAL PIVOTAL TRIAL SCHEDULED FOR Q4 2025, WITH ENROLLMENT OF ADDITIONAL PATIENTS EXPECTED TO CONTINUE AT MULTIPLE SITES THIS QUARTER PRESENTED NEW SUPPLEMENTAL ANALYSIS OF PART A REVEAL DATA REINFORCING THE BROAD AND CONSISTENT, MULTI-DOMAIN IMPACT OF TSHA-102 ON ACTIVITIES OF DAILY LIVING AT THE CNS ANNUAL MEETING TSHA-102 CONTINUES TO BE GENERALLY WELL TOLERATED WITH NO TREATMENT-RELATED SAES OR DLTS IN THE 12 PATIENTS TREATED IN THE PART A REVEAL PHASE 1/2 TRIALS AS OF OCTOBER 2025DATA CUTOFF REGAINED FULL UNENCUMBERED RIGHTS TO TSHA-102 RETT SYNDROME PROGRAM, ENABLING TAYSHA TO FOCUS ON DRIVING LONG-TERM VALUE WITH FULL STRATEGIC FLEXIBILITY AND OPTIONALITY CONFERENCE CALL AND WEBCAST TODAY AT8:30 AM EASTERN TIME DALLAS, NOV. 04, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDEDSEPTEMBER 30, 2025, AND PROVIDED A CORPORATE UPDATE. THE PROGRESS WE'VE MADE IN THE THIRD QUARTER OF 2025 SETS THE STAGE FOR A POTENTIALLY TRANSFORMATIVE PERIOD AHEAD FOR TAYSHA.

TAYSHA GENE THERAPIES REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

DALLAS, OCT. 28, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THAT IT WILL REPORT ITS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND HOST A CORPORATE UPDATE CONFERENCE CALL AND WEBCAST ON TUESDAY, NOVEMBER 4, 2025, AT 8:30 AM EASTERN TIME.

TAYSHA GENE THERAPIES TO RELEASE THIRD QUARTER 2025 FINANCIAL RESULTS AND HOST CONFERENCE CALL AND WEBCAST ON NOVEMBER 4

THE 2022 OPTION AGREEMENT BETWEEN ASTELLAS AND TAYSHA HAS EXPIRED REGAINING FULL RIGHTS TO TSHA-102 RETT SYNDROME PROGRAM ENABLES TAYSHA TO FOCUS ON DRIVING ITS LONG-TERM VALUE WITH FULL STRATEGIC FLEXIBILITY AND OPTIONALITY TSHA-102 HAS DEMONSTRATED COMPELLING PART A REVEAL PHASE 1/2 SAFETY AND EFFICACY DATA, RECEIVED FDA BREAKTHROUGH THERAPY DESIGNATION AND IS ADVANCING WITH A CLEAR PATH TO POTENTIAL REGISTRATION DOSING OF THE FIRST PATIENT IN THE REVEAL PIVOTAL TRIAL IS SCHEDULED THIS QUARTER DALLAS, OCT. 16, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THAT THE COMPANY HAS REGAINED FULL RIGHTS TO ITS LEAD TSHA-102 PROGRAM IN CLINICAL EVALUATION FOR RETT SYNDROME. THE 2022 OPTION AGREEMENT BETWEEN ASTELLAS AND TAYSHA, WHICH HAD GRANTED ASTELLAS THE EXCLUSIVE OPTION TO ENTER A NEGOTIATION PERIOD TO OBTAIN AN EXCLUSIVE LICENSE TO TSHA-102 IN RETT SYNDROME AND CERTAIN RIGHTS WITH RESPECT TO CHANGE IN CONTROL TRANSACTIONS INVOLVING TAYSHA, HAS EXPIRED.

TAYSHA GENE THERAPIES REGAINS FULL RIGHTS TO LEAD TSHA-102 PROGRAM IN CLINICAL EVALUATION FOR THE TREATMENT OF RETT SYNDROME

PREVIOUSLY DISCLOSED 100% RESPONSE RATE ACROSS ALL 10 PATIENTS IN PART A FOR PIVOTAL TRIAL PRIMARY ENDPOINT OF GAIN/REGAIN OF  ONE NATURAL HISTORY DEFINED DEVELOPMENTAL MILESTONE ASSESSED VIA VIDEO-EVIDENCED REVIEW BY INDEPENDENT CENTRAL RATERS NEW SUPPLEMENTAL ANALYSIS OF VALIDATED, STRUCTURED EFFICACY SCALES PROVIDES SUPPORTIVE EVIDENCE OF ADDITIONAL FUNCTIONAL GAINS, WITH 100% OF PATIENTS DEMONSTRATING MULTIPLE SKILL GAINS/IMPROVEMENTS OUTSIDE THE NATURAL HISTORY DEFINED DEVELOPMENTAL MILESTONES FINDINGS REINFORCE THE BROAD AND CONSISTENT FUNCTIONAL GAINS SEEN ACROSS THE CORE DOMAINS THAT IMPACT ACTIVITIES OF DAILY LIVING, WITH 22 DEVELOPMENTAL MILESTONES AND 165 ADDITIONAL SKILLS/IMPROVEMENTS ACHIEVED ACROSS THE 10 PATIENTS POST-TSHA-102 DALLAS, OCT. 09, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED RESULTS FROM A NEW SUPPLEMENTAL DATA ANALYSIS FROM PART A OF THE REVEAL PHASE 1/2 ADULT/ADOLESCENT AND PEDIATRIC TRIALS EVALUATING TSHA-102 IN FEMALES WITH RETT SYNDROME AT THE 54TH CHILD NEUROLOGY SOCIETY (CNS) ANNUAL MEETING. THE ANALYSIS PROVIDES SUPPORTIVE EVIDENCE OF ADDITIONAL FUNCTIONAL GAINS IN SKILLS AND IMPROVEMENTS ACROSS CORE DISEASE CHARACTERISTICS THAT ARE OUTSIDE OF THE NATURAL HISTORY DEFINED DEVELOPMENTAL MILESTONES, FURTHER HIGHLIGHTING THE CONSISTENT, MULTI-DOMAIN IMPACT OF TSHA-102 ON ACTIVITIES OF DAILY LIVING.

TAYSHA GENE THERAPIES PRESENTS NEW SUPPLEMENTAL DATA ANALYSIS FROM PART A OF THE REVEAL PHASE 1/2 TRIALS FOR TSHA-102 IN RETT SYNDROME AT THE 54TH CNS ANNUAL MEETING

DALLAS, OCT. 03, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THAT, ON OCTOBER 1, 2025, THE COMPENSATION COMMITTEE OF TAYSHA'S BOARD OF DIRECTORS GRANTED SEVEN NEW EMPLOYEES, IN THE AGGREGATE, OPTIONS TO PURCHASE 1,289,600 SHARES OF THE COMPANY'S COMMON STOCK IN CONNECTION WITH THEIR EMPLOYMENT. THE STOCK OPTIONS WERE GRANTED UNDER THE TAYSHA GENE THERAPIES, INC. 2023 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE INDIVIDUALS ENTERING EMPLOYMENT WITH TAYSHA IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

TAYSHA GENE THERAPIES ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

BREAKTHROUGH THERAPY DESIGNATION GRANTED BASED ON FDA'S REVIEW OF AVAILABLE CLINICAL EVIDENCE OF SAFETY AND EFFICACY FROM ALL 12 PATIENTS TREATED IN PART A OF THE REVEAL PHASE 1/2 TRIALS FINALIZED FDA ALIGNMENT ON REVEAL PIVOTAL TRIAL PROTOCOL AND SAP FOLLOWING RESOLUTION OF REMAINING CLINICAL AND STATISTICAL QUERIES TO IND APPLICATION AMENDMENT; ON TRACK TO BEGIN PATIENT ENROLLMENT IN Q4 2025 KEY PIVOTAL TRIAL DESIGN ELEMENTS REMAIN UNCHANGED, INCLUDING 6-MONTH INTERIM ANALYSIS TO POTENTIALLY EXPEDITE BLA SUBMISSION BASED ON THE RIGOROUS DEVELOPMENTAL MILESTONE EVALUATION IN PART A SHOWING AN UNPRECEDENTED RESPONSE RATE AT 6 MONTHS POST-TSHA-102 THAT DEEPENED OVER TIME DALLAS, OCT. 02, 2025 (GLOBE NEWSWIRE) -- TAYSHA GENE THERAPIES, INC. (NASDAQ: TSHA) (TAYSHA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON ADVANCING ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPIES FOR SEVERE MONOGENIC DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS), TODAY ANNOUNCED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED BREAKTHROUGH THERAPY DESIGNATION TO TSHA-102, AN INTRATHECALLY DELIVERED AAV9 GENE THERAPY WITH DISEASE MODIFYING POTENTIAL, FOR THE TREATMENT OF RETT SYNDROME. ADDITIONALLY, THE COMPANY ANNOUNCED THAT IT HAS FINALIZED ALIGNMENT WITH THE FDA ON THE REVEAL PIVOTAL TRIAL PROTOCOL AND STATISTICAL ANALYSIS PLAN (SAP) THAT ARE INTENDED TO SUPPORT THE PLANNED BIOLOGICS LICENSE APPLICATION (BLA) SUBMISSION FOR TSHA-102, FOLLOWING THE RESOLUTION OF REMAINING CLINICAL AND STATISTICAL QUERIES.

Taysha Gene Therapies, Inc.

TSHA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Taysha Gene Therapies, Inc.

TSHA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TSHA